责任编辑:觅健苏苏
参考文献:
[1]郑维锋.HER2阳性乳腺癌靶向药物的研究进展[J].中国肿瘤生物治疗杂志,2022,29(6):587-595.
[2]黎立喜,马飞.恩美曲妥珠单抗在乳腺癌中的临床研究进展[J].中华肿瘤杂志,2021,43(1):92-97.
[3]段海明,吴昊,刘娟,苟学龙.抗体药物偶联物DS-8201a在晚期乳腺癌中的研究进展[J].中国肿瘤临床,2021,48(12):640-643.
[4]Cortés J, Kim SB, Chung WP, et al; DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med. 2022 Mar 24;386(12):1143-1154.
[5]Erika P, et al. Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03. 2022 ASCO. Abstract: 1000.
[6]曾铖,张剑.抗体偶联药物应用于乳腺癌治疗的研究进展[J].中国临床新医学,2022,15(6):477-481.
[7]中国抗癌协会肿瘤药物临床研究专业委员会,国家抗肿瘤药物临床应用监测专家委员会,国家肿瘤质控中心乳腺癌专家委员会,北京市肿瘤治疗质量控制和改进中心肿瘤化疗质控专家委员会.抗体药物偶联物治疗恶性肿瘤临床应用专家共识(2020版)[J].中国医学前沿杂志(电子版),2021,13(1):1-15.
[8]辽宁省药品和医用耗材集中采购网.
[9]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2-positive-breast-cancer
[10]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-enhertu-fam-trastuzumab-deruxtecan-nxki-adult-patients
[11]https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-approved-in-eu-for-her2-positive-mbc.html
[12]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer
[13]Trastuzumab Deruxtecan(DS8201)药品说明书.
[14]https://www.pharmacychecker.com/enhertu/?src=drug-suggest#us-prices
点分享
点收藏
点点赞
点在看
联系客服